Health-care companies rose as traders rotated into high-risk areas such as biotechnology.
Health-care companies rose as traders rotated into high-risk areas such as biotechnology.
Moderna shares rose 9% as a breakthrough in skin-cancer vaccines, divulged earlier this week, continued to stoke investor excitement. Merck, Moderna's partner on the melanoma product, also gained.
The iShares Biotechnology exchange-traded fund, a basket of major biotech companies, rose by more than 2%, closing at an all-time high.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
Biotech Is Booming, But These 2 Stocks Missed the Memo - Moderna (NASDAQ:MRNA), iShares Biotechnology ETF
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial Gains - Pfizer (NYSE:PFE), Mode
Why Is Moderna Stock Down Today?
Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)
MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks Today - Moderna (NASDAQ:MRNA)
For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars
Moderna Is Just The Start: Why AI-Focused Money Might Flow Into Biotech
Why Is BioNTech Stock Surging on Wednesday? - BioNTech (NASDAQ:BNTX)
Moderna and Merck shares soar on mRNA cancer vaccine
Moderna stock drops 12% after 177% surge: Here’s what Wall Street says about MRNA
Health-care companies rose as traders continued to rotate out of high-risk artificial-intelligence stocks into lagging sectors.
Health-care companies fell as euphoria about a breakthrough in RNA-based medicine faded.
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
Health-care companies rose after a breakthrough at the intersection of vaccines and oncology.
Health-care companies rose as traders rotated into some lagging sectors.
Health-care companies ticked down as traders rotated out of defensive sectors into technology companies.
